| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/04/1996 | WO1996010087A1 Method for treatment of cancers by regulating the activity of ras proteins |
| 04/04/1996 | WO1996010080A1 Finderons and methods of their preparation and use |
| 04/04/1996 | WO1996010038A1 Multifunctional molecular complexes for gene transfer to cells |
| 04/04/1996 | WO1996009835A1 Novel mitogen activated protein kinase, frk |
| 04/04/1996 | WO1996008274A3 Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents |
| 04/04/1996 | WO1995030763A3 Retroviral vectors having a reduced recombination rate |
| 04/04/1996 | DE4445562C1 Klonierung, Expression und Charakterisierung einer neuen Form der Phosphatidylinositol-3-Kinase Cloning, expression and characterization of a new form of phosphatidylinositol 3-kinase |
| 04/04/1996 | CA2208599A1 Tissue specific hypoxia regulated therapeutic constructs |
| 04/04/1996 | CA2200845A1 Finderons and methods of their preparation and use |
| 04/04/1996 | CA2197904A1 Deffective recombinant adenoviruses with inactivated iva2 gene |
| 04/04/1996 | CA2197657A1 Novel mitogen activated protein kinase, frk |
| 04/03/1996 | EP0704534A2 Recombinant DNA viral vector for transfecting animal cells |
| 04/03/1996 | EP0704533A1 An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus |
| 04/03/1996 | EP0704526A1 hTFIIIA gene |
| 04/03/1996 | EP0704221A2 A conjugate useful in gene transfer and a method of producing the same |
| 04/03/1996 | EP0703988A1 Mesothelial cell gene therapy |
| 04/03/1996 | EP0703979A1 Method for treating kaposi's sarcoma with antisense oligonucleotides |
| 04/03/1996 | EP0703920A1 Myeloid cell leukemia associated gene mcl-1 |
| 04/03/1996 | CN1119830A Antisense inhibition of C-MYC to modulate the proliferation of smooth muscle cells |
| 03/28/1996 | WO1996009408A1 Human galactokinase gene |
| 03/28/1996 | WO1996009399A2 Chimeric adenovirus for gene delivery |
| 03/28/1996 | WO1996009392A1 RIBOZYME TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF PLASMA LIPOPROTEIN (a) [Lp(a)] BY INHIBITING APOLIPOPROTEIN (a) [APO(a)] |
| 03/28/1996 | WO1996009387A1 Cancer treatment by expression of differentiation factor receptor |
| 03/28/1996 | WO1996009385A1 Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease |
| 03/28/1996 | WO1996009380A1 Method of enhancing expression of mhc class i molecules bearing endogenous peptides |
| 03/28/1996 | WO1996009374A1 Human galactokinase gene |
| 03/28/1996 | WO1996009373A1 Fibroblasts for the treatment of muscular disorders |
| 03/28/1996 | WO1996009311A1 Human transcription factor iia |
| 03/28/1996 | WO1996009074A1 Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
| 03/28/1996 | WO1996008970A1 COMPOSITIONS AND METHODS FOR THE ABROGATION OF CELLULAR PROLIFERATION UTILIZING THE HUMAN IMMUNODEFICIENCY VIRUS Vpr PROTEIN |
| 03/28/1996 | WO1996007738A3 Modified human c3 proteins |
| 03/28/1996 | CA2200835A1 Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
| 03/28/1996 | CA2200724A1 Human galactokinase gene |
| 03/28/1996 | CA2200611A1 Cancer treatment by expression of differentiation factor receptor |
| 03/28/1996 | CA2199727A1 Ribozyme treatment of diseases or conditions related to levels of plasma lipoprotein (a) ¬lp(a)| by inhibiting apolipoprotein (a) ¬apo(a)| |
| 03/28/1996 | CA2198379A1 Fibroblasts for the treatment of muscular disorders |
| 03/27/1996 | EP0702723A1 Biocompatible implant for the expression and secretion in vivo of a therapeutical compound |
| 03/27/1996 | EP0702722A1 Plasmids suitable for gene therapy |
| 03/27/1996 | EP0702717A1 Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors |
| 03/27/1996 | EP0702716A1 Ribozyme gene therapy for hiv infection and aids |
| 03/27/1996 | EP0702566A1 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity |
| 03/27/1996 | EP0702518A1 Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
| 03/27/1996 | EP0702516A1 Genetic immunization with cationic lipids |
| 03/27/1996 | CN1119459A Process for preparing cancer vaccines |
| 03/27/1996 | CN1119458A Nucleic acid pharmaceuticals |
| 03/26/1996 | US5501969 Bone disorders, antitumor |
| 03/21/1996 | WO1996008574A1 Novel implant and novel vector for the treatment of acquired diseases |
| 03/21/1996 | WO1996008560A1 Transduction of genes into human hematopoietic stem cells using recombinant adeno-associated viral vectors |
| 03/21/1996 | WO1996008557A1 Human inositol monophosphatase h1 |
| 03/21/1996 | WO1996008510A1 Hu-B1.219, A NOVEL HUMAN HEMATOPOIETIN RECEPTOR |
| 03/21/1996 | WO1996008275A1 Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
| 03/21/1996 | WO1996008274A2 Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents |
| 03/21/1996 | WO1996008268A1 Inhibition of endothelin-1 to reduce inflammatory processes |
| 03/21/1996 | WO1996008260A1 MUTANT ACTIVATED Gsα* AND ADENYLYL CYCLASE 2 FOR USE AS THERAPEUTIC AGENTS |
| 03/21/1996 | WO1996005309A3 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| 03/21/1996 | DE4432942A1 New synthetic inducible biological response amplifier |
| 03/21/1996 | CA2199939A1 Inhibition of endothelin-1 to reduce inflammatory processes |
| 03/21/1996 | CA2199746A1 Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
| 03/20/1996 | EP0702084A1 Recombinant retroviruses |
| 03/20/1996 | EP0701609A1 Inhibition of proliferation of vascular smooth muscle cell |
| 03/20/1996 | EP0701563A1 Gene transfer for treating a connective tissue of a mammalian host |
| 03/20/1996 | EP0701450A1 Recombinant viruses and their use in gene therapy |
| 03/20/1996 | EP0701401A1 Adenoviral vectors including dna encoding lung surfactant protein |
| 03/14/1996 | WO1996007748A1 Non self-inactivating, expression targeted retroviral vectors |
| 03/14/1996 | WO1996007747A1 Retroviral vector hybrids and the use thereof for gene transfer |
| 03/14/1996 | WO1996007741A1 Protein targeting into hiv virions based on hiv-1 vpr fusion molecules |
| 03/14/1996 | WO1996007738A2 Modified human c3 proteins |
| 03/14/1996 | WO1996007734A2 Recombinant adenovirus comprising a chimeric penton base protein |
| 03/14/1996 | WO1996007433A1 Gene therapy drug for cancer, medicinal composition, and therapeutic method |
| 03/14/1996 | WO1996007322A1 Method of sensitizing tumor cells with adenovirus e1a |
| 03/14/1996 | WO1996007321A1 Methods for modulating protein function in cells using intracellular antibody homologues |
| 03/14/1996 | WO1996006168A3 Retinoblastoma protein-interacting zinc finger proteins |
| 03/14/1996 | WO1996005307A3 17q-linked breast and ovarian cancer susceptibility gene |
| 03/14/1996 | WO1996005306A3 In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene |
| 03/14/1996 | WO1996002556A3 Oligonucleotides with anti-mdr-1 gene activity |
| 03/14/1996 | DE19503952A1 Retrovirale Vektorhybride und deren Verwendung zum Gentransfer Retroviral vector hybrids and their use for gene transfer |
| 03/14/1996 | CA2199265A1 Method of sensitizing tumor cells with adenovirus e1a |
| 03/14/1996 | CA2198861A1 Recombinant adenovirus comprising a chimeric penton base protein |
| 03/14/1996 | CA2198621A1 Protein targeting into hiv virions based on hiv-1 vpr fusion molecules |
| 03/14/1996 | CA2197888A1 Modified human c3 proteins |
| 03/13/1996 | EP0700928A1 Nucleic acid-binding oligomers for therapy and diagnostics |
| 03/13/1996 | EP0700430A1 Methods for selectively stimulating proliferation of t cells |
| 03/07/1996 | WO1996006943A1 Cell cycle regulated repressor and dna element |
| 03/07/1996 | WO1996006942A1 Genetically altered t-cells |
| 03/07/1996 | WO1996006941A1 Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle |
| 03/07/1996 | WO1996006940A1 Genetic therapy of tumours with an endothelium cell-specific active substance which is dependent on the cell cycle |
| 03/07/1996 | WO1996006939A1 Genetic therapy of diseases of the central nervous system with a cell-specific active substance which is dependent on the cell cycle |
| 03/07/1996 | WO1996006938A1 Genetic therapy of vascular diseases with a cell-specific active substance which is dependent on the cell cycle |
| 03/07/1996 | WO1996006937A1 Improvements in production of proteins in host cells |
| 03/07/1996 | WO1996006933A1 Gene therapy for transplantation and inflammatory or thrombotic conditions |
| 03/07/1996 | WO1996006862A1 Gabaa receptor epsilon subunit |
| 03/07/1996 | WO1996006860A2 Gradual modification, super-agonists and antagonists of signal-proteins and peptides |
| 03/07/1996 | WO1996006641A1 Conjugates of vascular endothelial growth factor with targeted agents |
| 03/07/1996 | WO1996003515A3 Surface expression of enzyme in gene directed prodrug therapy |
| 03/07/1996 | DE19531931A1 Modulatoren des Körpergewichts, korrespondierende Nukleinsäuren und Proteine, und diagnostische und therapeutische Verwendungen derselben Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| 03/07/1996 | CA2198919A1 Gradual modification, super agonists and antagonists of signs and peptides |
| 03/07/1996 | CA2198891A1 Genetically modified t cells |
| 03/07/1996 | CA2198474A1 Genetic therapy of diseases of the central nervous system with a cell-specific active substance which is dependent on the cell cycle |
| 03/07/1996 | CA2198473A1 Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound |
| 03/07/1996 | CA2198472A1 Genetic therapy of vascular diseases with a cell-specific active substance which is dependent on the cell cycle |